Despite no press announcements from either the owner of the Musculoskeletal Clinical Regulatory Advisors, LLC (aka: MCRA) or its acquirer, North Carolina-based IQVIA, MCRA is now an IQVIA company. LinkedIn said so.
IQVIA Buys MCRA
1 min read Premium comments
#iqvia#mcra#vbllc
Founded in 2004 by Anthony, Mark, and John Viscogliosi and managed all these years by David Lown, the Musculoskeletal Clinical Regulatory Advisors (MCRA) became the #1 advisor to companies young and old, for clinical research, reimbursement, and regulatory matters.
Over the years MCRA was the straw that stirred the drink for one groundbreaking musculoskeletal technology after another. As the firm’s reputation grew, it attracted top talent from the very regulatory agencies it worked with. That, in turn, created a virtuous cycle that led MCRA to expand beyond its origins in the orthopedic and spine world.
Today, MCRA is the premier regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, due diligence and distribution logistics advisory firm for orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity.
To support its broad mandate, MCRA has offices in Washington, DC, Hartford, Connecticut, New York, New York, London, England, Winterthur, Switzerland, Eschborn, Germany and Tokyo, Japan and serves nearly 1,000 clients globally.
IQVIA, MCRA’s new owner, is the largest supplier of life sciences data and advisory services on the globe.
IQVIA sales from selling data, advanced analytics, technology solutions, and clinical research services to the life sciences industry reached $15 billion for the last 12 months. Thirty-six thousand people work at IQVIA in approximately 100 countries.
Finally, it cannot be overstated that this transaction is simply the latest in a multi-decade series of marketable and remarkable accomplishments on the part of the Viscogliosi Brothers.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.